An article titled ‘Bridging the Gap: Transforming Multiomic Endpoints into Actionable Human Disease Discoveries,’ published in SelectScience®. It features a guest editorial by Dr. Matt Westfall, Senior Director of Biochemical Pharmacology and Proteomics at Inotiv, who discusses the Strategic Synergy: The Inotiv-VUGENE Translational Engine.
In the current era of drug discovery, the primary challenge is no longer the generation of data, but its translation. While technological advances have made multiomics a daily reality, a fundamental hurdle remains: how to distill the biological findings from model organisms into a “wiring diagram” that is truly reflective of human disease.
Dr. Westfall shares that the next frontier is cross-species model qualification. He views the bridging of multiomics data from in vivo and in vitro models to human disease biology as the definitive frontier for drug discovery.
“The challenge is not related to the generation of large data sets within a model, but evaluating the translational fidelity of that model,” Dr. Westfall explains. “We need to determine how precisely the molecular signatures in a model reflect human biochemistry and clinical phenotypes. Selecting a model with high human relevance saves significant costs during drug discovery and may also result in an accelerated transition to clinical trials.”
He highlights a critical issue: traditional analysis often fails to bridge the gap between preclinical models and clinical outcomes. That’s where VUGENE comes in.
VUGENE’s platform is purpose-built to address the “translational gap” through three core pillars:
- Comprehensive disease and model characterization: Conducting in-depth multiomic profiling to thoroughly understand the biological landscape of both the disease state and its preclinical models.
- Identification of cross-species and multiomic patterns: Pinpointing the conserved molecular signatures that persist across species and multiple layers of biological regulatory proteins.
- Mechanistic alignment to human disease biology: Translating complex model discoveries into biologically plausible human frameworks, ensuring that therapeutic targets identified in the lab are mapped directly to relevant human clinical phenotypes.
Read full article: Link
Published by: SelectScience® on January 30, 2026
Cover photo credits: InfiniteFlow
